APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lung Tumor Ablation

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lung Tumor Ablation Market Outlook and Growth Opportunities 2026

4 July 2026192 pages

Choose your research edition.

Industry ResearchLung Tumor Ablation Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Lung Tumor Ablation Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Lung Tumor Ablation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lung Tumor Ablation Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Lung Tumor Ablation Market Analysis and Forecast 2026-2032173 pages · $4,950 USD

Market perspective

The global Lung Tumor Ablation market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lung Tumor Ablation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lung Tumor Ablation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lung Tumor Ablation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lung Tumor Ablation market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lung Tumor Ablation market include Angiodynamics, Auris Health, Intuitive Surgica, Nanjing MICRO-TECH, Smith and Nephew, VISON Medical, Olympus, Boston Scientific and Broncus, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Lung Tumor Ablation market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lung Tumor Ablation and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lung Tumor Ablation revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Lung Tumor Ablation market.

Lung Tumor Ablation Segment by Company

Angiodynamics

Auris Health

Intuitive Surgica

Nanjing MICRO-TECH

Smith and Nephew

VISON Medical

Olympus

Boston Scientific

Broncus

LungCare

Medtronic

TIPC

Lung Tumor Ablation Segment by Type

Microwave Ablation (MWA)

Radiofrequency Ablation (RFA)

Cold Ablation

Others

Lung Tumor Ablation Segment by Application

Hospitals

Ambulatory Surgical Centers

Lung Tumor Ablation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lung Tumor Ablation status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Lung Tumor Ablation key companies, revenue, market share, and recent developments.

3. To split the Lung Tumor Ablation breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Lung Tumor Ablation market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lung Tumor Ablation significant trends, drivers, influence factors in global and regions.

6. To analyze Lung Tumor Ablation competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Tumor Ablation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lung Tumor Ablation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Tumor Ablation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lung Tumor Ablation industry.

Chapter 3: Detailed analysis of Lung Tumor Ablation company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Lung Tumor Ablation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Lung Tumor Ablation in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lung Tumor Ablation Industry Trends Table 2. Lung Tumor Ablation Industry Drivers Table 3. Lung Tumor Ablation Industry Opportunities and Challenges Table 4. Lung Tumor Ablation Industry Restraints Table 5. Global Lung Tumor Ablation Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lung Tumor Ablation Revenue Share by Company (2021-2026) Table 7. Global Lung Tumor Ablation Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Lung Tumor Ablation Key Company Manufacturing Base & Headquarters Table 9. Global Lung Tumor Ablation Company, Product Type & Application Table 10. Global Lung Tumor Ablation Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Lung Tumor Ablation by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Microwave Ablation (MWA) Table 15. Significant Companies of Radiofrequency Ablation (RFA) Table 16. Significant Companies of Cold Ablation Table 17. Significant Companies of Others Table 18. Global Lung Tumor Ablation Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Lung Tumor Ablation Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Lung Tumor Ablation Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Lung Tumor Ablation Sales Value Share by Type (2021-2026) Table 22. Global Lung Tumor Ablation Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Ambulatory Surgical Centers Table 25. Global Lung Tumor Ablation Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Lung Tumor Ablation Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Lung Tumor Ablation Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Lung Tumor Ablation Sales Value Share by Application (2021-2026) Table 29. Global Lung Tumor Ablation Sales Value Share by Application (2027-2032) Table 30. Global Lung Tumor Ablation Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Lung Tumor Ablation Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Lung Tumor Ablation Sales Value Share by Region (2021-2026) Table 33. Global Lung Tumor Ablation Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Lung Tumor Ablation Sales Value Share by Region (2027-2032) Table 35. Global Lung Tumor Ablation Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Lung Tumor Ablation Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Lung Tumor Ablation Sales Value Market Share by Country (2021-2026) Table 38. Global Lung Tumor Ablation Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Lung Tumor Ablation Sales Value Market Share by Country (2027-2032) Table 40. Angiodynamics Company Information Table 41. Angiodynamics Business Overview Table 42. Angiodynamics Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Angiodynamics Lung Tumor Ablation Product Portfolio Table 44. Angiodynamics Recent Development Table 45. Auris Health Company Information Table 46. Auris Health Business Overview Table 47. Auris Health Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Auris Health Lung Tumor Ablation Product Portfolio Table 49. Auris Health Recent Development Table 50. Intuitive Surgica Company Information Table 51. Intuitive Surgica Business Overview Table 52. Intuitive Surgica Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Intuitive Surgica Lung Tumor Ablation Product Portfolio Table 54. Intuitive Surgica Recent Development Table 55. Nanjing MICRO-TECH Company Information Table 56. Nanjing MICRO-TECH Business Overview Table 57. Nanjing MICRO-TECH Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Nanjing MICRO-TECH Lung Tumor Ablation Product Portfolio Table 59. Nanjing MICRO-TECH Recent Development Table 60. Smith and Nephew Company Information Table 61. Smith and Nephew Business Overview Table 62. Smith and Nephew Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Smith and Nephew Lung Tumor Ablation Product Portfolio Table 64. Smith and Nephew Recent Development Table 65. VISON Medical Company Information Table 66. VISON Medical Business Overview Table 67. VISON Medical Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. VISON Medical Lung Tumor Ablation Product Portfolio Table 69. VISON Medical Recent Development Table 70. Olympus Company Information Table 71. Olympus Business Overview Table 72. Olympus Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Olympus Lung Tumor Ablation Product Portfolio Table 74. Olympus Recent Development Table 75. Boston Scientific Company Information Table 76. Boston Scientific Business Overview Table 77. Boston Scientific Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Boston Scientific Lung Tumor Ablation Product Portfolio Table 79. Boston Scientific Recent Development Table 80. Broncus Company Information Table 81. Broncus Business Overview Table 82. Broncus Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Broncus Lung Tumor Ablation Product Portfolio Table 84. Broncus Recent Development Table 85. LungCare Company Information Table 86. LungCare Business Overview Table 87. LungCare Lung Tumor Ablation Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. LungCare Lung Tumor Ablation Product Portfolio Table 89. LungCare Recent Development Table 90. Medtronic Company Information Table 91. Medtronic Business Overview Table 92. Medtronic Lung Tumor Ablation Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Medtronic Lung Tumor Ablation Product Portfolio Table 94. Medtronic Recent Development Table 95. TIPC Company Information Table 96. TIPC Business Overview Table 97. TIPC Lung Tumor Ablation Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. TIPC Lung Tumor Ablation Product Portfolio Table 99. TIPC Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Lung Tumor Ablation Product Image Figure 2. Global Lung Tumor Ablation Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lung Tumor Ablation Market Size (2021-2032) & (US$ Million) Figure 4. Global Lung Tumor Ablation Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Microwave Ablation (MWA) Image Figure 8. Radiofrequency Ablation (RFA) Image Figure 9. Cold Ablation Image Figure 10. Others Image Figure 11. Global Lung Tumor Ablation Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Lung Tumor Ablation Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Lung Tumor Ablation Sales Value Share by Type (2021-2032) Figure 14. Hospitals Image Figure 15. Ambulatory Surgical Centers Image Figure 16. Global Lung Tumor Ablation Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Lung Tumor Ablation Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Lung Tumor Ablation Sales Value Share by Application (2021-2032) Figure 19. Global Lung Tumor Ablation Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Lung Tumor Ablation Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Lung Tumor Ablation Sales Value (2021-2032) & (US$ Million) Figure 22. North America Lung Tumor Ablation Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Lung Tumor Ablation Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Lung Tumor Ablation Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Lung Tumor Ablation Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Lung Tumor Ablation Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Lung Tumor Ablation Sales Value (2021-2032) & (US$ Million) Figure 28. South America Lung Tumor Ablation Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Lung Tumor Ablation Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Lung Tumor Ablation Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Lung Tumor Ablation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Microwave Ablation (MWA)
  • Radiofrequency Ablation (RFA)
  • Cold Ablation
  • Others
Applications
  • Hospitals
  • Ambulatory Surgical Centers
Companies covered
  • Angiodynamics
  • Auris Health
  • Intuitive Surgica
  • Nanjing MICRO-TECH
  • Smith and Nephew
  • VISON Medical
  • Olympus
  • Boston Scientific
  • Broncus
  • LungCare
  • Medtronic
  • TIPC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lung Tumor Ablation Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lung Tumor Ablation Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Lung Tumor Ablation Market Dynamics
  1. 2.1 Lung Tumor Ablation Industry Trends
  2. 2.2 Lung Tumor Ablation Industry Drivers
  3. 2.3 Lung Tumor Ablation Industry Opportunities and Challenges
  4. 2.4 Lung Tumor Ablation Industry Restraints
3 Lung Tumor Ablation Market by Company
  1. 3.1 Global Lung Tumor Ablation Company Revenue Ranking in 2025
  2. 3.2 Global Lung Tumor Ablation Revenue by Company (2021-2026)
  3. 3.3 Global Lung Tumor Ablation Company Ranking (2024-2026)
  4. 3.4 Global Lung Tumor Ablation Company Manufacturing Base and Headquarters
  5. 3.5 Global Lung Tumor Ablation Company Product Type and Application
  6. 3.6 Global Lung Tumor Ablation Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Lung Tumor Ablation Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Lung Tumor Ablation Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Lung Tumor Ablation Market by Type
  1. 4.1 Lung Tumor Ablation Type Introduction
  2. 4.1.1 Microwave Ablation (MWA)
  3. 4.1.2 Radiofrequency Ablation (RFA)
  4. 4.1.3 Cold Ablation
  5. 4.1.4 Others
  6. 4.2 Global Lung Tumor Ablation Sales Value by Type
  7. 4.2.1 Global Lung Tumor Ablation Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Lung Tumor Ablation Sales Value by Type (2021-2032)
  9. 4.2.3 Global Lung Tumor Ablation Sales Value Share by Type (2021-2032)
5 Lung Tumor Ablation Market by Application
  1. 5.1 Lung Tumor Ablation Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Ambulatory Surgical Centers
  4. 5.2 Global Lung Tumor Ablation Sales Value by Application
  5. 5.2.1 Global Lung Tumor Ablation Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Lung Tumor Ablation Sales Value by Application (2021-2032)
  7. 5.2.3 Global Lung Tumor Ablation Sales Value Share by Application (2021-2032)
6 Lung Tumor Ablation Regional Value Analysis
  1. 6.1 Global Lung Tumor Ablation Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lung Tumor Ablation Sales Value by Region (2021-2032)
  3. 6.2.1 Global Lung Tumor Ablation Sales Value by Region: 2021-2026
  4. 6.2.2 Global Lung Tumor Ablation Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lung Tumor Ablation Sales Value (2021-2032)
  7. 6.3.2 North America Lung Tumor Ablation Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Lung Tumor Ablation Sales Value (2021-2032)
  10. 6.4.2 Europe Lung Tumor Ablation Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Lung Tumor Ablation Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Lung Tumor Ablation Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Lung Tumor Ablation Sales Value (2021-2032)
  16. 6.6.2 South America Lung Tumor Ablation Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Lung Tumor Ablation Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Lung Tumor Ablation Sales Value Share by Country, 2025 VS 2032
7 Lung Tumor Ablation Country-level Value Analysis
  1. 7.1 Global Lung Tumor Ablation Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lung Tumor Ablation Sales Value by Country (2021-2032)
  3. 7.2.1 Global Lung Tumor Ablation Sales Value by Country (2021-2026)
  4. 7.2.2 Global Lung Tumor Ablation Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Lung Tumor Ablation Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Lung Tumor Ablation Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Lung Tumor Ablation Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Angiodynamics
  2. 8.1.1 Angiodynamics Company Information
  3. 8.1.2 Angiodynamics Business Overview
  4. 8.1.3 Angiodynamics Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Angiodynamics Lung Tumor Ablation Product Portfolio
  6. 8.1.5 Angiodynamics Recent Developments
  7. 8.2 Auris Health
  8. 8.2.1 Auris Health Company Information
  9. 8.2.2 Auris Health Business Overview
  10. 8.2.3 Auris Health Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Auris Health Lung Tumor Ablation Product Portfolio
  12. 8.2.5 Auris Health Recent Developments
  13. 8.3 Intuitive Surgica
  14. 8.3.1 Intuitive Surgica Company Information
  15. 8.3.2 Intuitive Surgica Business Overview
  16. 8.3.3 Intuitive Surgica Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Intuitive Surgica Lung Tumor Ablation Product Portfolio
  18. 8.3.5 Intuitive Surgica Recent Developments
  19. 8.4 Nanjing MICRO-TECH
  20. 8.4.1 Nanjing MICRO-TECH Company Information
  21. 8.4.2 Nanjing MICRO-TECH Business Overview
  22. 8.4.3 Nanjing MICRO-TECH Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Nanjing MICRO-TECH Lung Tumor Ablation Product Portfolio
  24. 8.4.5 Nanjing MICRO-TECH Recent Developments
  25. 8.5 Smith and Nephew
  26. 8.5.1 Smith and Nephew Company Information
  27. 8.5.2 Smith and Nephew Business Overview
  28. 8.5.3 Smith and Nephew Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Smith and Nephew Lung Tumor Ablation Product Portfolio
  30. 8.5.5 Smith and Nephew Recent Developments
  31. 8.6 VISON Medical
  32. 8.6.1 VISON Medical Company Information
  33. 8.6.2 VISON Medical Business Overview
  34. 8.6.3 VISON Medical Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  35. 8.6.4 VISON Medical Lung Tumor Ablation Product Portfolio
  36. 8.6.5 VISON Medical Recent Developments
  37. 8.7 Olympus
  38. 8.7.1 Olympus Company Information
  39. 8.7.2 Olympus Business Overview
  40. 8.7.3 Olympus Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Olympus Lung Tumor Ablation Product Portfolio
  42. 8.7.5 Olympus Recent Developments
  43. 8.8 Boston Scientific
  44. 8.8.1 Boston Scientific Company Information
  45. 8.8.2 Boston Scientific Business Overview
  46. 8.8.3 Boston Scientific Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Boston Scientific Lung Tumor Ablation Product Portfolio
  48. 8.8.5 Boston Scientific Recent Developments
  49. 8.9 Broncus
  50. 8.9.1 Broncus Company Information
  51. 8.9.2 Broncus Business Overview
  52. 8.9.3 Broncus Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Broncus Lung Tumor Ablation Product Portfolio
  54. 8.9.5 Broncus Recent Developments
  55. 8.10 LungCare
  56. 8.10.1 LungCare Company Information
  57. 8.10.2 LungCare Business Overview
  58. 8.10.3 LungCare Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  59. 8.10.4 LungCare Lung Tumor Ablation Product Portfolio
  60. 8.10.5 LungCare Recent Developments
  61. 8.11 Medtronic
  62. 8.11.1 Medtronic Company Information
  63. 8.11.2 Medtronic Business Overview
  64. 8.11.3 Medtronic Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Medtronic Lung Tumor Ablation Product Portfolio
  66. 8.11.5 Medtronic Recent Developments
  67. 8.12 TIPC
  68. 8.12.1 TIPC Company Information
  69. 8.12.2 TIPC Business Overview
  70. 8.12.3 TIPC Lung Tumor Ablation Revenue and Gross Margin (2021-2026)
  71. 8.12.4 TIPC Lung Tumor Ablation Product Portfolio
  72. 8.12.5 TIPC Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst